AURO-LEVETIRACETAM 250 levetiracetam 250 mg tablets Bottle

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

levetiracetam, Quantity: 250 mg

Disponível em:

Strides Pharma Science Pty Ltd

DCI (Denominação Comum Internacional):

Levetiracetam

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: purified talc; magnesium stearate; povidone; colloidal anhydrous silica; maize starch; titanium dioxide; hypromellose; indigo carmine; macrogol 4000

Via de administração:

Oral

Unidades em pacote:

60, 30

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

It is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME),and,? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (IGE).

Resumo do produto:

Visual Identification: Blue, oval shaped, biconvex film-coated tablets debossed with a deep break line separating 'E' and '10' on one side and plain on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status de autorização:

Licence status A

Data de autorização:

2011-12-23